These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21892035)

  • 61. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?
    Kostakoglu L; Goldsmith SJ
    Eur J Nucl Med; 2000 Oct; 27(10):1564-78. PubMed ID: 11083548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Spontaneous regression of follicular, mantle cell, and diffuse large B-cell non-Hodgkin's lymphomas detected by FDG-PET imaging.
    Kumar R; Bhargava P; Zhuang H; Yu JQ; Schuster SJ; Alavi A
    Clin Nucl Med; 2004 Nov; 29(11):685-8. PubMed ID: 15483478
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nodal staging of lymphoma with whole-body PET: comparison of.
    Sutinen E; Jyrkkiö S; Varpula M; Lindholm P; Grönroos T; Lehikoinen P; Teräs M; Minn H
    J Nucl Med; 2000 Dec; 41(12):1980-8. PubMed ID: 11138682
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma.
    Sonet A; Graux C; Nollevaux MC; Krug B; Bosly A; Vander Borght T
    Ann Hematol; 2007 Jan; 86(1):9-15. PubMed ID: 17021839
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDG PET-CT in the management of primary breast lymphoma.
    Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
    Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 18F-FDG-PET/CT in staging, recurrence detection and response evaluation of primary splenic lymphoma with eight years follow up.
    Karunanithi S; Roy SG; Murugan V; Bal C; Kumar R
    Nucl Med Rev Cent East Eur; 2015; 18(1):37-8. PubMed ID: 25633516
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The utility of body FDG PET in staging primary central nervous system lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Neuro Oncol; 2008 Apr; 10(2):223-8. PubMed ID: 18287338
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow.
    Nihashi T; Hayasaka K; Itou T; Sobajima T; Kato R; Ito K; Ito Y; Ishigaki T; Naganawa S
    Radiat Med; 2007 Apr; 25(3):130-4. PubMed ID: 17450338
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PET and restaging of malignant lymphoma including residual masses and relapse.
    Reske SN
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S89-96. PubMed ID: 12748829
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [18F]-FDG positron imaging in clinical management of lymphoma patients.
    Talbot JN; Haioun C; Rain JD; Meignan M; Wioland M; Misset JL; Grahek D; Kerrou K; Montravers F
    Crit Rev Oncol Hematol; 2001 Jun; 38(3):193-221. PubMed ID: 11369254
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PET scans in the staging of lymphoma: current status.
    Friedberg JW; Chengazi V
    Oncologist; 2003; 8(5):438-47. PubMed ID: 14530496
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FDG PET/CT imaging suggests lymphoma involving prostate may be more resistant to treatment.
    Li G; Dhawan M; Takalkar AM; Lilien DL
    Clin Nucl Med; 2011 Mar; 36(3):255-7. PubMed ID: 21285695
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of FDG-PET scans in patients with lymphoma.
    Seam P; Juweid ME; Cheson BD
    Blood; 2007 Nov; 110(10):3507-16. PubMed ID: 17709603
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.
    Even-Sapir E; Israel O
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S65-81. PubMed ID: 12644887
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pediatric Extranodal Lymphoma.
    Chung EM; Pavio M
    Radiol Clin North Am; 2016 Jul; 54(4):727-46. PubMed ID: 27265605
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lymphomatous involvement of epididymis: detection and response assessment with (18)F-FDG PET/CT.
    Dhull VS; Sharma P; Singla S; Khangembam BC; Bal C; Kumar R
    Clin Nucl Med; 2013 Jun; 38(6):e271-2. PubMed ID: 23510888
    [TBL] [Abstract][Full Text] [Related]  

  • 79. FDG-PET scans in patients with lymphoma.
    Elstrom RL; Leonard JP
    Curr Hematol Malig Rep; 2008 Oct; 3(4):197-203. PubMed ID: 20425466
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Lymphoma in children and adolescents].
    Sorge I; Georgi TW; Hirsch FW
    Radiologe; 2021 Jul; 61(7):611-618. PubMed ID: 34160645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.